Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Alkotinib PK in Healthy Subjects
NCT04032821Phase 1Completed
- Sponsor
- Zelgen
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alkotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Zelgen. Primary endpoints: Maximum Plasma Concentration up to 120 hours, Area Under the Curve from time zero to last measurable concentration up to 120 hours and 1 more. Started Nov 2019; status: completed.
02
Drugs
alkotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04032821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032821.